We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
Read MoreHide Full Article
Shares of Pacira BioSciences (PCRX - Free Report) have surged 66.8% in the past six months against the industry’s decline of 8.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe.
Strong quarterly results, consistent growth in sales of lead drug Exparel and encouraging pipeline progress have boosted investor sentiment.
PCRX Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
Exparel’s Performance Fuels PCRX Growth
Exparel, Pacira’s flagship pain-management product, continues to drive sales. The drug is indicated for postsurgical local analgesia in patients aged six years and older. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.
The Centers for Medicare and Medicaid Services issued a permanent product-specific J-code (J0666) for Pacira’s Exparel to facilitate better insurance coverage for the drug. The new J-code became effective Jan. 1, 2025.
In December 2024, Pacira received the 940 patent from the U.S. Patent and Trademark Office that protects the chemical composition of Exparel ensuring protection against generics in the market through 2044. This ensures the drug’s exclusivity in the pain management market, thereby preventing generic erosion.
PCRX Efforts to Expand Exparel Bode Well
Pacira is seeking to further expand Exparel’s label to treat younger age groups, which should increase the target patient population. The company is launching a phase I pharmacokinetic study to support the expansion of a single-dose infiltration label to include patients under six years of age. Subject to the success of this study, Pacira plans to initiate a phase III registration study to support regulatory filings seeking label expansions in the United States and the EU.
The company is also interacting with regulatory bodies around the world for the use of Exparel as a nerve block in the pediatric setting.
Other Drugs in PCRX Portfolio
Apart from Exparel, PCRX has two other non-opioid treatments: Zilretta and iovera. Zilretta is approved as an extended-release intra-articular therapy providing relief to OA patients with knee pain while iovera is a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
These drugs generate incremental sales and boost the top line.
Pacira is also currently looking to expand Zilretta’s indication to include treatment for OA pain in the shoulder. The company initiated a phase III study to evaluate the efficacy of Zilretta in shoulder OA. Based on the success of the study, the company plans to seek label expansion of the drug for this indication.
Subject to approval, this will further drive up Zilretta sales which could relieve some of the burden on Exparel sales to generate revenues.
PCRX is also looking to broaden its portfolio with the development of PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like OA.
Dependence on Exparel is a Headwind
Pacira is heavily dependent on Exparel for growth since the drug accounts for a significant chunk of its revenues. Exparel contributed approximately 78% of the company’s total revenues in 2024.
A decline in Exparel due to generics will impact the top line as the other products are yet to gain traction. In addition, a lean pipeline further adds to the company’s dependence on these products for growth in the near future.
Valuation & Estimates
Going by the price/sales ratio, PCRX is trading cheap. Pacira’s shares currently trade at 1.45x forward sales, lower than its mean of 3.04x and the industry’s 1.70x.
Image Source: Zacks Investment Research
The estimate for 2025 earnings per share has decreased to $3.24 from $3.46 over the past 30 days. Nonetheless, the same for 2025 has increased 14 cents.
Image Source: Zacks Investment Research
Stay Invested in PCRX for Now
Pacira’s Exparel maintains momentum for it and additional label expansion of the drug should drive growth.
However, the exceptional rally witnessed by the stock might limit any further gains. The company’s sole dependence on Exparel and a lean pipeline are added concerns.
Other players in the biotech industry who have weathered the market volatility well and put up a strong performance are Gilead Sciences, Inc. (GILD - Free Report) and Dynavax Technologies (DVAX - Free Report) .
We advise prospective investors to wait for now before turning positive for PCRX. For investors already owning the stock, staying invested would be a prudent move.
Image: Bigstock
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
Shares of Pacira BioSciences (PCRX - Free Report) have surged 66.8% in the past six months against the industry’s decline of 8.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe.
Strong quarterly results, consistent growth in sales of lead drug Exparel and encouraging pipeline progress have boosted investor sentiment.
PCRX Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
Exparel’s Performance Fuels PCRX Growth
Exparel, Pacira’s flagship pain-management product, continues to drive sales. The drug is indicated for postsurgical local analgesia in patients aged six years and older. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.
The Centers for Medicare and Medicaid Services issued a permanent product-specific J-code (J0666) for Pacira’s Exparel to facilitate better insurance coverage for the drug. The new J-code became effective Jan. 1, 2025.
In December 2024, Pacira received the 940 patent from the U.S. Patent and Trademark Office that protects the chemical composition of Exparel ensuring protection against generics in the market through 2044. This ensures the drug’s exclusivity in the pain management market, thereby preventing generic erosion.
PCRX Efforts to Expand Exparel Bode Well
Pacira is seeking to further expand Exparel’s label to treat younger age groups, which should increase the target patient population. The company is launching a phase I pharmacokinetic study to support the expansion of a single-dose infiltration label to include patients under six years of age. Subject to the success of this study, Pacira plans to initiate a phase III registration study to support regulatory filings seeking label expansions in the United States and the EU.
The company is also interacting with regulatory bodies around the world for the use of Exparel as a nerve block in the pediatric setting.
Other Drugs in PCRX Portfolio
Apart from Exparel, PCRX has two other non-opioid treatments: Zilretta and iovera. Zilretta is approved as an extended-release intra-articular therapy providing relief to OA patients with knee pain while iovera is a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
These drugs generate incremental sales and boost the top line.
Pacira is also currently looking to expand Zilretta’s indication to include treatment for OA pain in the shoulder. The company initiated a phase III study to evaluate the efficacy of Zilretta in shoulder OA. Based on the success of the study, the company plans to seek label expansion of the drug for this indication.
Subject to approval, this will further drive up Zilretta sales which could relieve some of the burden on Exparel sales to generate revenues.
PCRX is also looking to broaden its portfolio with the development of PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like OA.
Dependence on Exparel is a Headwind
Pacira is heavily dependent on Exparel for growth since the drug accounts for a significant chunk of its revenues. Exparel contributed approximately 78% of the company’s total revenues in 2024.
A decline in Exparel due to generics will impact the top line as the other products are yet to gain traction. In addition, a lean pipeline further adds to the company’s dependence on these products for growth in the near future.
Valuation & Estimates
Going by the price/sales ratio, PCRX is trading cheap. Pacira’s shares currently trade at 1.45x forward sales, lower than its mean of 3.04x and the industry’s 1.70x.
Image Source: Zacks Investment Research
The estimate for 2025 earnings per share has decreased to $3.24 from $3.46 over the past 30 days. Nonetheless, the same for 2025 has increased 14 cents.
Image Source: Zacks Investment Research
Stay Invested in PCRX for Now
Pacira’s Exparel maintains momentum for it and additional label expansion of the drug should drive growth.
However, the exceptional rally witnessed by the stock might limit any further gains. The company’s sole dependence on Exparel and a lean pipeline are added concerns.
Other players in the biotech industry who have weathered the market volatility well and put up a strong performance are Gilead Sciences, Inc. (GILD - Free Report) and Dynavax Technologies (DVAX - Free Report) .
We advise prospective investors to wait for now before turning positive for PCRX. For investors already owning the stock, staying invested would be a prudent move.
PCRX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.